The Novosibirsk State Pedagogical University (NSPU) and the Federal Research Center for Fundamental and Translational Medicine (FRC FTM) have developed an antioxidant TC-13 to reduce the negative impact of chemotherapy in oncology. This was reported by the press service of the university.
The development has no analogues in the world.
The water-soluble antioxidant TC-13 obtained by Novosibirsk specialists effectively mitigates the undesirable general toxic and cardiotoxic manifestations of antitumor anthracycline therapy.
The studies were conducted on rats. One group was exposed to the antitumor drug doxorubicin, while in the other, doxorubicin was used in combination with the antioxidant TC-13.
The results showed that the experimental animals in the second group improved functional activity of the heart, they did not lose weight. In the first group, rodents showed a deterioration in heart function in all respects, they lost 21% of their total body weight.
Antioxidant TC-13 activates the antitumor activity of doxorubicin and reduces its toxicity. The developers plan to begin clinical trials.
Earlier www1.ru reported that new antioxidants were discovered in Perm.
Read related materials:
Cancer defeated?: A revolutionary vaccine against all types of cancer has been developed in Russia
Rosatom has developed a new technology for producing a drug for cancer treatment
A Russian soluble patch implant has been developed for the treatment of oncological diseases